Subtitle: Market Intelligence, Emerging Metabolic Therapies, and High-Purity Reagents for Insulin Sensitization and Oncology Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GRB14 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRB14 Full-Length / SH2 Domain / Ras-associating Domain Recombinant Proteins. High purity (>95%), E. coli/HEK293 Expressed, Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. | View GRB14 Products |
| Gene Delivery | GRB14 Lentivirus Premade Particles. Full-length ORF for stable cell line construction (HepG2, L6). | View GRB14 Products |
| Benchmark Ab | Anti-GRB14 Detection Antibody (Research & Diagnostic Grade). Recombinant positive control for Western blot, ELISA, and IP. | View GRB14 Products |
| Validator | GRB14 siRNA Set (3 unique sequences). For transient knockdown, off-target screening, and specificity verification in metabolic cell models. | View GRB14 Products |
| Related Target | INSR (Insulin Receptor). Direct binding partner; essential for Co-IP, signaling rescue, and PPI inhibition assays. | View INSR Products |
| Related Target | IGF1R (IGF-I Receptor). Parallel growth factor axis; key for paralog selectivity screening and oncology resistance modeling. | View IGF1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI Selectivity (vs. GRB7/GRB10) | GRB14-Specific SH2 Domain (>95% purity) vs. GRB10/GRB7 Ortholog Panels strictly verified by mass spec. |
| Phospho-Binding Validation | High-affinity binding to pY-peptides from INSR/IGF1R; Mutant controls (R→A) included for specificity checks. |
| Functional Cell Line Generation | Lentivirus for stable GRB14 overexpression/knockdown; Ready for insulin signaling assays (p-AKT rescue). |
| Lack of Structural Controls | Wild-Type + Loss-of-Function Mutant Proteins (e.g., R458A) for differential SPR/ITC and binding validation. |
| Intracellular Phenotypic False Positives | Validated siRNA included to decouple target-specific effects from off-target noise. |
Live GRB14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GRB14 therapeutics is intensifying as metabolic disease research pivots toward insulin sensitization mechanisms beyond traditional PPAR agonists. As a critical negative regulator of the Insulin Receptor (INSR) and IGF1R, GRB14 inhibition represents a novel avenue for Type 2 Diabetes and Non-Alcoholic Steatohepatitis (NASH) treatment. The next wave of R&D is targeting precision protein-protein interaction (PPI) inhibitors and liver-specific siRNA knockdown strategies to enhance insulin signaling without the side effects associated with pan-GRB inhibition. Currently, GRB14 is in early discovery and preclinical validation, with no disclosed Phase II or III programs. The field is shifting from broad-spectrum kinase approaches toward precision modulation of adapter protein interactions. Future interest includes combination regimens alongside incretin-based therapies (e.g., GLP-1 agonists) to address residual insulin resistance.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SH2 Domain Inhibitor) | Academic Consortia, Early Biotech | Type 2 Diabetes, NASH | GRB14 SH2 Domain purity >95% for FP/SPR binding assays. Need selectivity vs. GRB7/GRB10. |
| siRNA / Gene Silencing | Metabolic Disease Focused Biotech, RNAi Developers | Hepatic Insulin Resistance, Obesity | siRNA Validation Sets + Lentivirus for stable knockdown lines and pathway analysis in hepatocyte models. |
| Stapled Peptide / Peptidomimetic | Peptide Engineering Labs, Preclinical Labs | Refractory Metabolic Syndrome, Solid Tumors | Full-length GRB14 & Ras-associating domain proteins for conformational assays and cell permeability testing. |
| PROTAC / Degrader | TPD Specialized Biotech, Platform Companies | Oncology (HER2+ breast, prostate), Metabolic | Wild-Type vs. Mutant GRB14 for degradation validation; HiBiT/GRB14 stable cell lines needed. |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Affinity & Selectivity: Inhibitors must achieve >100-fold selectivity over GRB7/GRB10 SH2 domains. TarMart provides homolog protein panels for counter-screening.
- Mechanism Validation: Block GRB14-INSR interaction using pY-peptide binding assays (FP, SPR) with purified SH2 domain.
- Mutant Controls: R458A (SH2 domain loss-of-function) is essential as a negative control. TarMart offers WT + R458A protein pairs.
- Delivery & Permeability: For intracellular targets, small molecules and peptides need cell penetration. TarMart lentivirus enables stable cell-based rescue assays.
Recommended Screening Cascade
| Step | Assay | TarMart Reagent |
|---|---|---|
| Primary Screen | Fluorescence Polarization (FP) / AlphaScreen | GRB14 SH2 domain (>95%) + biotin-pY-INSR peptide |
| Selectivity | Competitive SPR vs. GRB7/GRB10 | GRB14/GRB7/GRB10 SH2 domain protein panel |
| Functional Rescue | Insulin signaling (p-AKT) rescue in hepatocytes | GRB14 overexpression lentivirus + siRNA |
| Degradation (PROTAC) | Ternary complex formation (AlphaLISA) | Full-length GRB14 + E3 ligase (VHL/CRBN) |
Related Target Recommendations
Based on the GRB14 signaling axis, the following targets are recommended for cross-selling and parallel assay development:
- INSR (Insulin Receptor): Direct binding partner for PPI inhibition and signaling rescue assays.
- IGF1R (Insulin-like Growth Factor 1 Receptor): Parallel RTK for selectivity screening and oncology resistance studies.
- GRB10 / GRB7: Essential paralog controls for counter-screening to avoid off-target toxicity.